Peptide inhibitors of hepatitis C virus NS3 protease

Details Peptide inhibitors of hepatitis C virus NS3 protease Peptide inhibitors of hepatitis C virus NS3 protease

2005-09-06

2005-09-06

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

06939854

ABSTRACT:
This invention relates to a novel class of peptides having the Formula (I):which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus (HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

REFERENCES:
patent: 6699855 (2004-03-01), Zhang et al.
patent: 6774212 (2004-08-01), Han
patent: WO 97/43310 (1997-11-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
Benet et al. Pharmacokinetics: The dynamics of Drug Absorption, Distribution, adn Elimination. McGraw-Hill (1990): 3-32 (see reference sent in parent application).
Manning et al. Stability of Protein Pharmaceuticals. Pharmaceutical Research (1989) 6: 903-918 (see reference sent in parent application).
Dimasi et al. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.J Virol. Oct. 1997;71(10):7461-9 (see reference sent in parent application).
C. Steinkuhler, et al, “Product Inhibition of the Hepatitis C Virus NS3 Protease,” BIOCHEMISTRY, 37, pp. 8899-8905, 1998.
P. Ingallinella, et al, “Potent Peptide Inhibitors of Human Hepatits C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products,” BIOCHEMISTRY, 37, pp. 8906-8914, 1998.
E. Pizzi, et al, “Molecular Model of the Specificity Pocket of the Hepatits C Virus Protease: Implications for Substrate Recognition,” Proc. Natl. Acad. Sci. USA, 91, pp. 888-892, 1994.
A. Urbani, et al, “Substrate Specificity of the Hepatitis C Virus Serine Protease NS3,” The Journal of Biological Chemistry, 272(14), pp. 9204-9209, 1997.
R. B. Perni, “NS3•4A Protease as a Target for Interfering with Hepatitis C Virus Replication,” Drug News Perspect, 13(2), pp. 69-77, 2000.

Affiliated with

Also associated with

Rating

Peptide inhibitors of hepatitis C virus NS3 protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide inhibitors of hepatitis C virus NS3 protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of hepatitis C virus NS3 protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3392107